<DOC>
	<DOCNO>NCT01760226</DOCNO>
	<brief_summary>The subject invite take part research study s/he diagnose Diffuse Large B-Cell Lymphoma ( DLBCL ) , Primary Mediastinal B-cell Lymphoma ( PMBCL ) , Post-transplant Lymphoproliferative Disorder ( PTLD ) . In attempt improve cure rate reduce harmful effect drug , oncologist develop new treatment protocol . One protocol , entitle dose-adjusted EPOCH-R , utilize two major new strategy . First , treatment approach utilize continuous infusion chemotherapy four day , instead administer minute hour . Secondly , dose medication involve increase decrease base drug affect subject 's ability produce blood cell , use measure rapidly body processing drug . Using approach adult , researcher show improved cure rate cancer . Additionally , harmful effect experience patient mild , mucositis , severe infection , tumor lysis syndrome occur rarely . However , new dose method never use child , effectiveness side effect new method unknown child . The purpose study look safety dose-adjusted EPOCH-R treatment child mature B-cell cancer , see maintain cure rate ( show adult ) . This study represent first trial dose-adjusted EPOCH-R child .</brief_summary>
	<brief_title>Dose Adjusted EPOCH-R , Treat Mature B Cell Malignancies</brief_title>
	<detailed_description>The subject need variety test , exam , procedure find s/he study . The subject also require placement catheter stay vein safe administration chemotherapy drug . During study ... If test do show s/he participate s/he choose participate , treatment cycle begin . A cycle equal three week . The subject minimum 6 cycle treatment , possibly 8 . The cancer drug s/he receive etoposide , vincristine , doxorubicin , cyclophosphamide , prednisone , rituximab cycle . The amount drug determine subject 's weight first , drug adjust later cycle . Rituximab give Day 1 prior continuous infusion drug . After 4 cycle , subject imaging scan see cancer respond treatment . If cancer respond completely 4 cycle , s/he get 2 cycle ( 6 cycle total ) . If cancer partially respond , s/he get 4 cycle ( 8 total cycle ) . If subject cancer Central Nervous System , s/he receive drug call methotrexate . If s/he cancer CNS , s/he get methotrexate try prevent CNS cancer .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patient newly diagnose , histologically confirm , Group B C diffuse large Bcell lymphoma ; primary mediastinal Bcell lymphoma . Patients Group B/C post transplant lymphoproliferative disorder eligible study regardless whether disease newly diagnose . ( Murphy stag use group classification . ) Patient receive previous chemotherapy radiation therapy previous 3 month , except empiric initial intrathecal administration diagnosis . Rituximab steroid administration exclusion criterion . Patient receive prior anthracyclines . Patient symptomatic cardiac failure unrelieved medical therapy evidence significant cardiac dysfunction echocardiogram ( shorten fraction &lt; 28 % ) NOT due mediastinal mass . Patient severe renal disease ( i.e . creatinine great 3 time normal age ; creatinine clearance le 50 ml/min/1.73m2 ) . Patient severe hepatic disease ( direct bilirubin great 3 mg/dl AST great 500 IU/L ) . Patient Karnofsky performance score &lt; 50 % Lansky score &lt; 50 % . HIVpositive patient exclude unless antiretroviral therapy safely withhold chemotherapy administration , base clinical determination infectious disease team evaluation . Female patient pregnant breastfeeding . Patient reproductive potential willing use acceptable method birth control ( i.e . hormonal contraception , intrauterine device , condom diaphragm spermicide , abstinence ) duration study one year post completion therapy . Patient primary central nervous system ( CNS ) lymphoma ( lymphoma limit craniospinal axis without systemic involvement ) Patient Burkitt cell lymphoma leukemia . Patient group classification A disease , group classification B stage I II disease normal LDH level AND tumor mass le 7 cm .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>Diffuse large B cell lymphoma</keyword>
	<keyword>dose adjust</keyword>
	<keyword>EPOCH</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Rituximab</keyword>
</DOC>